T. Rowe Price Investment Management
PRME icon

T. Rowe Price Investment Management’s Prime Medicine PRME Stock Holding History

T. Rowe Price Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Sell
5,237,332
-244,561
-4% -$812K 0.01% 551
2026
Q1 		$19.1M Sell
5,481,893
-513,290
-9% -$1.95M 0.01% 471
2025
Q4 		$20.8M Sell
5,995,183
-3,221,914
-35% -$14.3M 0.01% 487
2025
Q3 		$51.1M Buy
9,217,097
+2,732,310
+42% +$11.1M 0.03% 385
2025
Q2 		$16M Buy
6,484,787
+2,341,691
+57% +$3.61M 0.01% 529
2025
Q1 		$8.24M Buy
4,143,096
+165,268
+4% +$422K 0.01% 568
2024
Q4 		$11.6M Buy
3,977,828
+170,541
+4% +$599K 0.01% 546
2024
Q3 		$14.7M Buy
3,807,287
+81,560
+2% +$378K 0.01% 538
2024
Q2 		$19.2M Buy
3,725,727
+635,644
+21% +$3.85M 0.01% 504
2024
Q1 		$21.6M Buy
+3,090,083
New +$23.4M 0.01% 493

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Investment Management's PRME Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its Prime Medicine (PRME) stake by 4.5% in Q2 2026, selling an estimated $812K and leaving 5,237,332 shares worth $19.3M. The position accounts for 0.01% of the portfolio, ranked #551.

T. Rowe Price Investment Management first reported a position in PRME in Q1 2024 and has held it in 10 quarters since. The position peaked at $51.1M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • T. Rowe Price Investment Management held 5,237,332 shares of Prime Medicine worth $19.3M as of Q2 2026.
  • T. Rowe Price Investment Management sold 244,561 Prime Medicine shares in Q2 2026, an estimated $812K.
  • Prime Medicine made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #551 holding.
  • T. Rowe Price Investment Management first reported a position in Prime Medicine in Q1 2024 and has held it in 10 quarters since.
  • T. Rowe Price Investment Management's Prime Medicine position peaked at $51.1M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.